RZLT Rezolute Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RZLT

Price (delayed)

$3.28

Market cap

$129.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.1

Enterprise value

$119.98M

Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric ...

Highlights
Rezolute's quick ratio has plunged by 50% YoY and by 16% from the previous quarter
Rezolute's equity has decreased by 35% YoY and by 11% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rezolutebio.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of RZLT
Market
Shares outstanding
39.63M
Market cap
$129.97M
Enterprise value
$119.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$56.83M
EBITDA
-$56.28M
Free cash flow
-$53M
Per share
EPS
-$1.1
Free cash flow per share
-$1.03
Book value per share
$2.31
Revenue per share
$0
TBVPS
$1.99
Balance sheet
Total assets
$102.15M
Total liabilities
$10.42M
Debt
$2.51M
Equity
$91.73M
Working capital
$88.08M
Liquidity
Debt to equity
0.03
Current ratio
12
Quick ratio
11.56
Net debt/EBITDA
0.18
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-48.1%
Return on equity
-51.8%
Return on invested capital
-58.6%
Return on capital employed
-60.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RZLT stock price

How has the Rezolute stock price performed over time
Intraday
10.44%
1 week
23.31%
1 month
37.82%
1 year
52.56%
YTD
230.48%
QTD
28.63%

Financial performance

How have Rezolute's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$62.49M
Net income
-$56.83M
Gross margin
N/A
Net margin
N/A
Rezolute's operating income has decreased by 34% YoY
Rezolute's net income has decreased by 29% YoY

Growth

What is Rezolute's growth rate over time

Valuation

What is Rezolute stock price valuation
P/E
N/A
P/B
1.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rezolute's EPS has decreased by 3.8% YoY
The stock's price to book (P/B) is 156% more than its last 4 quarters average of 0.5
Rezolute's equity has decreased by 35% YoY and by 11% QoQ

Efficiency

How efficient is Rezolute business performance
The company's return on invested capital has surged by 96% YoY and by 21% QoQ
The ROE is down by 46% year-on-year and by 12% since the previous quarter
RZLT's return on assets is down by 44% year-on-year and by 11% since the previous quarter

Dividends

What is RZLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RZLT.

Financial health

How did Rezolute financials performed over time
Rezolute's quick ratio has plunged by 50% YoY and by 16% from the previous quarter
Rezolute's current ratio has decreased by 49% YoY and by 16% from the previous quarter
RZLT's debt is 97% smaller than its equity
RZLT's debt to equity has surged by 50% since the previous quarter and by 50% year-on-year
Rezolute's equity has decreased by 35% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.